Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFRA3 | O60609 | 7/20 | 0.52 |
| ▸ | RET | P07949 | 3/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | GFRA2 | O00451 | 4/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | GFRA1 | P56159 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16841443 | 0.93 | GFRA3 (0.49) | GFRA3RETFFAR4FFAR1GFRA2 | |
| SCHEMBL1745543 | 0.89 | FFAR1 (0.51) | GFRA3RETFFAR4FFAR1AKR1B1 | |
| SCHEMBL1744798 | 0.83 | FFAR1 (0.53) | GFRA3RETFFAR4FFAR1AKR1B1 | |
| SCHEMBL1745124 | 0.81 | GFRA3 (0.52) | GFRA3RETFFAR4FFAR1GFRA2 | |
| SCHEMBL1632826 | 0.78 | FFAR1 (0.64) | FFAR4FFAR1AKR1B1 | |
| SCHEMBL15679163 | 0.78 | FFAR1 (0.36) | GFRA3RETFFAR4FFAR1AKR1B1 | |
| SCHEMBL1745473 | 0.77 | FFAR1 (0.48) | GFRA3RETFFAR4FFAR1AKR1B1 | |
| SCHEMBL1744587 | 0.77 | RXRA (0.58) | FFAR4FFAR1AKR1B1 | |
| SCHEMBL1744979 | 0.77 | FFAR1 (0.54) | GFRA3RETFFAR4FFAR1AKR1B1 | |
| SCHEMBL14567251 | 0.76 | FFAR1 (0.50) | GFRA3RETFFAR4FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388153-B2 | Secondary amines as therapeutic agents | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2015094864-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175567-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175567-A1 | SECONDARY AMINES AS THERAPEUTIC AGENTS | PDE6G, PDE3A, TYR | GFRA3 1030/4885RET 1511/4885FFAR4 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.